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Abstract
Rationale—We have employed nasal challenge with lipopolysaccharide (LPS) followed by nasal
lavage (NL) to experimentally induce and examine upper airway inflammation in human
volunteers. It is unclear however whether adaptation within individuals occurs following repeated
nasal challenge. This was a pilot study to determine if repeated nasal LPS challenge yields
attenuation of markers of inflammation (primarily neutrophil response) in the NL fluid of healthy
humans.
Methods—We employed a 3-day nasal LPS challenge protocol with NL using a “split nose”
design. The control and LPS nares received two consecutive day saline (0.9% saline/day) and LPS
(2 μg LPS/day) challenges, respectively followed by an LPS (2 μg/day) challenge to each nare on
Day 3. NL was performed immediately pre Day 1 challenges and 6-h post nasal LPS challenges on
both Days 1 and 3. Markers of inflammation (PMNs/mg, cytokines) were assessed in NL and the
inflammatory response to LPS (measured as the difference between pre and post challenge) was
evaluated in both nares on Day 3 and compared to Day 1.
Results—Significant (p < 0.05) blunting of the LPS-induced polymorphonuclear leukocyte
(PMN) response was observed in the nare that received repeated LPS challenges as compared to
the control nare (67.60 ± 22.39 vs. 157.8 ± 76.04 PMN/mg) and initial LPS challenge on Day 1
(121 ± 32 PMN/mg). Decreased soluble CD14 and significantly decreased interleukin-8 were also
found in the repeat LPS-treated nare. In the LPS-treated nare, the blunted PMN response on Day 3
correlated well with the observed PMN response on Day1 (r = 0.58, p = 0.02).
Conclusions—We show attenuation of PMN response to repeated LPS in the nasal airways in
healthy humans. Effect of repeat endotoxin exposure prior to allergen delivery on local airway
inflammation in both healthy and atopic subjects can be studied.
Copyright © 2011 Informa Healthcare USA, Inc.
Address for Correspondence: David B. Peden, peden@med.unc.edu..
Declaration of interest
V.D., N.E.A. and H.Z. do not have any conflicts of interest to report.
NIH Public Access
Author Manuscript
Inhal Toxicol. Author manuscript; available in PMC 2013 October 28.
Published in final edited form as:














Airway inflammation; neutrophils; adaptation; lipopolysaccharide (LPS, endotoxin)
Introduction
Endotoxin is a constituent of outer layer of Gram-negative bacteria. Lipopolysaccharide
(LPS) is the main component of endotoxin and is formed by the phosphogylcolipid A that is
covalently linked to hydrophilic hetero-polysaccharide and is responsible for its toxicity
(Rietschel et al., 1994). Endotoxin is found in various concentrations in house dust and
certain occupational settings like livestock, lab animals, grain and vegetable agriculture, saw
and cotton mills, waste management, fiberglass manufacturing and “sick buildings.” LPS
that is bound to LPS binding protein ligates the TLR4-CD14-MD2 complex on macrophages
and antigen-presenting cells, resulting in production of pro-inflammatory cytokines tumor
necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8, IL-12 and interferon-γ (IFN-γ), as
well as increased neutrophilic inflammation.
The spectrum of illnesses reported to be induced by endotoxin exposure include “Monday
Asthma” of cotton workers (Schneiter et al., 1942), humidifier fever (Mamolen et al., 1993;
Rylander and Haglind 1984), grain fever(Schwartz et al., 1995) toxic pneumonitis (Rylander
and Malmberg 1992), and acute systemic effects like malaise or fever (Milton et al., 1995)
to acute high level exposure. Repeated exposure causes chronic obstructive lung disease
without the acute effects (Christiani et al., 1993) and chronic exposure to low-level
concentrations can cause development of obstructive lung disease including emphysema,
chronic bronchitis and asthma (Niven et al., 1997; Pal et al., 1997; Sigsgaard et al., 1992;
Simpson et al., 1998). All these imply that increasing inflammation results from continued
exposure to endotoxin. On the other hand, there are increasing reports from cohort studies in
farming communities from Europe of lower incidence of atopy with increasing exposures of
LPS (Doreswamy and Peden, 2011). Children from farming households had about 30–50%
lower incidence of hay fever, hay fever symptoms in the past year and atopic sensitization.
(Braun-Fahrländer et al., 2002). Interestingly, production of IFN-γ, TNF-α, IL-12, IL-10 all
decreased with increasing endotoxin exposures implying long-term high level LPS exposure
could result in hyporesponsiveness.
Endotoxin tolerance is defined as reduced responsiveness to LPS challenge following a prior
encounter with LPS/endotoxin. Various terminologies are used to describe this and include
attenuation, adaptation, hyporesponsiveness, desensitization, immunoparalysis or
reprogramming (Fan and Cook 2004). The phenomenon and mechanisms of endotoxin
tolerance has been well established in animal and in vitro human models (Biswas and
Lopez-Collazo 2009; Cavaillon et al., 2003; West and Heagy 2002). Draisma et al., recently
explored the effect of repeat systemic administration of low-dose LPS in humans and
showed attenuation in response (Draisma et al., 2009). To our knowledge, experimental
studies examining the impact of repeated in vivo LPS exposure to the human airways have
not been undertaken. We were interested to see the effect of giving LPS repeatedly into
nasal airways of healthy subjects. Our primary endpoint was the change in neutrophil
(PMN) numbers obtained from nasal lavage (NL). We looked at secondary endpoints
including selected cytokines and soluble CD14 (sCD14). We show attenuation of PMN
response in the nostril that received three daily doses of LPS as compared to Day 1 on same
side and the contra-lateral nostril which received LPS only on Day 3.
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“Split nose” design with NL—This was a pilot study to assess the nasal PMN response
to LPS following repeated nasal exposure to LPS. The “split nose” design and NL procedure
have been described previously (Eldridge and Peden 2000a; Peden et al., 1995; Peden 1996).
Figure 1 shows the study design. A low dose of LPS (2 μg E. Coli #L-2262, Sigma, Inc., St.
Louis, MO) was applied to the same nare on two consecutive days, then again (2 μg) on the
third day (Day 3). At the same time, saline (0.9%) was applied to the contra-lateral nare for
two consecutive days, then LPS (2 μg) on Day 3. Baseline NL was performed on Day 1
followed immediately by LPS/saline challenge. NL was performed 6 h following the
challenges on Days 1 and 3. No NL was performed following challenges on Day 2.
Subjects
Fifteen (N = 15) healthy, non-allergic subjects between the ages of 18 and 50 were recruited
for the study. Informed consent was obtained prior to subject participation. The study was
approved by the Committee on the Protection of the Rights of Human Subjects, School of
Medicine, and The University of North Carolina, Chapel Hill. Subjects were non-smoking
(for at least 1 year) males or females that were in good health and free from any upper
respiratory tract illness for at least 6 weeks prior to study.
NL was performed as follows: 4 ml of normal saline were sprayed into the nares using a
table top nebulizer (DeVilbiss UltraNeb 99, Sunrise Medical) that delivered 100 μl/
actuation. Each lavage consisted of eight sets of five sprays. The lavage fluid was recovered
by forceful expulsion into a specimen cup immediately following each set of five actuations.
The samples were then transported to the laboratory on ice and processed immediately.
Cell count and soluble mediators recovered in NL fluid
The NL fluid was weighed and treated with a volume 0.1% dithiothreitol (Sputalysin 10%,
Calbiochem Corp., San Diego, CA) equal to two times the weight (mg) followed by the
addition of an equal volume of Dulbecco's phosphate buffered saline. The cell suspension
was filtered through a 70 μm nylon filter (Falcon cell strainer #2350, Becton Dickinson
Labware, Franklin Lakes, NJ) and the resulting suspension used for total cell count (TCC)
and cell viability (Trypan Blue exclusion staining). Cytospins were prepared (Shandon III
with a modified Wright's-Giemsa stain (Hema 3, Biochemical Sciences Inc., Swedesboro,
NJ) for differential leukocyte cell counts. The remaining cell suspension was centrifuged
and the supernatant aspirated and stored at −80°C for later assay.
Supernatant concentrations of IL-8, IL-6, IL-10, IL-1β, sCD14 and Granulocyte-
macrophage–colony-stimulating factor (GM-CSF), were determined using commercially
available enzyme-linked immunosor-bent assay (ELISA) kits (Endogen Inc., Woburn, MA;
Bioxytech, Oxis International Inc., Portland, OR; R&D Systems, Minneapolis, MN). The
cell viability was >50% on all samples. The limits of detection for IL-8, GM-CSF and
sCD14 were 2.0 pg/ml, 2.0 pg/ml and 125 pg/ml, respectively. The limits of detection for
IL-6, IL-10 and IL-1β were between 1 and 10 pg/ml. Eosinophil cationic protein
concentrations were determined with a sensitive radioimmunoassay (RIA, Kabi Pharmacia
Diagnostics AB, Uppsala, Sweden) with a minimum detection limit of 2.0 μg/l.
Statistical methods
Data represents values from all 15 subjects unless specifically noted. Paired t-tests were
used to analyze differences between LPS and saline treatments. Results were expressed as
the mean ± SEM. For hypothesis testing, log transformation was applied to the PMN data to
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ensure a normal distribution of the data. PMN response is defined as difference between
baseline-adjusted PMN levels following Day 1 and Day 3 LPS challenges, i.e., pre-
challenge numbers were subtracted from numbers obtained after each of the challenges for
each individual subject. Differences between variables were considered statistically
significant at p < 0.05.
Results
Characterization of subjects
All subjects tolerated the repeat LPS challenges without symptoms. Three of the fifteen
subjects were nonresponders. Subject characteristics and baseline lung function are
presented in Table 1.
Total and differential cell counts recovered in NL fluid on Day 1
Table 2 shows total and differential cell counts (mean ± SEM) pre- and post-LPS/saline
challenges. Significantly higher (TCC/mg) and absolute PMNs (cells/mg) were observed
following LPS (2 μg) vs. saline (0.9%) challenge (p < 0.05). Compared to pre-challenge,
there were significantly (p < 0.05) higher PMNs in the LPS nare, but not the saline nare.
PMN levels following LPS/saline challenge on Day 1
Figure 2 shows that a significantly increased number of PMNs were recovered in NL
following LPS (dark bar) vs. saline (open bar) challenge (p < 0.05).
PMN Response Following LPS Challenge on Day 3
In Figure 3, the nare that received repeated LPS challenge (dark bar), the PMN response was
significantly reduced by 57% (p = 0.03) compared to the nare that received repeated saline
challenge (open bar). Compared to the LPS-induced PMN response on Day 1 (spotted bar),
the PMN response on Day 3 in the LPS pre-treated nare was reduced by 44% (p = 0.05). In
contrast, the PMN response on Day 3 in the nare that received repeated saline challenges
(Figure 3 and Table 3) was significantly increased compared to its own Day 1 response
(Figure 2) (p = 0.03) and similar to the Day 1 PMN response in the LPS nare. This latter
observation provides evidence of the integrity of the split nose design where similar PMN
responses would have been expected between Day 1 (LPS nare) and Day 3 (saline nare) had
LPS challenge of the repeat LPS nare not affected the control nare. In the LPS-treated nare,
the blunted PMN response on Day 3 correlated well with the observed PMN response on
Day 1 (r = 0.58, p = 0.02).
sCD14 levels following LPS challenge on Day 3
Like the PMN response, sCD14 levels were also affected by repeat LPS challenge. In Figure
4, sCD14 levels were lower and trending toward significance (p = 0.06) in the nare that
received repeated LPS challenge (dark bar) compared to the saline nare (open bar). Day 3
sCD14 levels in the LPS nare were also decreased compared to the levels recovered from the
LPS nare on Day 1 (5067 ± 911 pg/ml vs. 6016 ± 1273 pg/ml). As expected, sCD14 levels
in the saline nare on Day 3 (open bar) were significantly elevated compared to the saline
nare on Day 1 (8610 ± 1713 vs. 4535 ± 832 pg/ml).
Fluid phase components recovered from NL on Day 3
Table 4 shows the concentration (mean ± SEM) of all fluid phase components recovered
from the saline and LPS pre-treated nares following LPS challenge on Day 3. All fluid phase
components (excluding GM-CSF) were decreased in the nare that received repeated LPS
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challenge vs. the saline control nare. Significantly decreased levels of IL-8 (*p = 0.03) were
observed in the LPS pre-treated nare compared to saline (Figure 5).
Discussion
Using a split nose design, we observed attenuation of response to LPS (as defined by a
blunted PMN response) in the nare that received repeated LPS challenges for 3 days but not
in the control nostril that received two saline repeated saline challenges before a single LPS
challenge. We also noted significantly lower IL-8 levels which parallels the PMN response
in the nare that received repeated LPS. To our knowledge, this is the first report of such
adaptation to endotoxin in a localized region of the human airway. This attenuation of LPS
response occurred only in the nare that received repeated LPS challenge, and was seen in the
absence of either parenteral endotoxin challenge or the presence of Gram-negative sepsis.
Therefore, it is very unlikely that a systemic tolerizing effect of endotoxin delivered to the
nasal airway accounts for this observation. Overall, these data suggest that attenuation of the
effect of LPS can occur at local tissues and confirms that adaptation to endotoxin can be
induced in the human airway in vivo.
This was a pilot study to determine effect of repeat LPS treatments in vivo and was not
designed to assess the underlying mechanism by which attenuation of LPS response occurs.
However, we did look at various inflammatory cytokines and sCD14 levels as additional
measures of LPS response. There was decrease of sCD14 levels in the nare with repeat LPS,
suggesting that a contributing mechanism of adaptation to LPS may involve lowering of
airway sCD14 levels. CD14 is a critical molecule for LPS response, and sCD14 could confer
ability to respond to LPS to epithelial cells which express TLR4 but not CD14. CD14
expression in airways is positively associated with inflammatory response to LPS (Alexis et
al., 2001). We have also shown in atopic asthmatics that decreases in membrane bound
CD14 on airway macrophages following inhaled corticosteroid treatment is associated with
decreased response to LPS (Alexis and Peden 2001). Delineation of cellular mechanisms for
attenuation of the response to LPS was beyond the scope of this pilot study.
Complex interaction exists between endotoxin and the development or progression of atopy
and asthma. Early life exposure to endotoxin has been shown to reduce the risk of atopy and
asthma while exposure once atopic sensitization has occurred seems to worsen it (Liu,
2002). Endotoxin accentuates eosinophil influx into airways of atopic asthmatics (Peden et
al., 1999). Low-level allergen challenge with Dust mite Der f prior to low-dose endotoxin
challenge enhances response to a single dose of endotoxin (Eldridge and Peden 2000b). It
would be interesting to explore the interaction of multiple low-dose LPS challenges on
subsequent allergen challenges. Interestingly, human bronchial epithelial cells also exhibited
tolerance with repeat exposure to Pseudomonas aeruginosa extracts as evidenced by reduced
nuclear factor-κB inhibitor degradation and IL-8 levels (Wu et al., 2005).
NL fluid was collected 6 h after LPS or saline challenge on Day 1 and LPS challenge on
Day 3. It is possible that collection of NLF at different time points might have yielded more
informative samples. Samples collected 30 min to 1 h after challenge might have
demonstrated a more robust IL-1β, IL-6 or IL-8 response to LPS, allowing for a more clear
comparison of cytokine responses to saline, LPS at baseline and LPS after repeated LPS
challenge. Likewise, any impact of repeated LPS challenge to sCD14 and IL-10 might have
been best appreciated immediately before challenge on Day 3 and not 6 h later. In this study,
we chose not to add more lavages to the protocol to minimize the potential for disruption of
the mediator milieu in the nasal mucosa. The 6-h post challenge time point was selected as
an optimal time to examine neutrophil influx to the nasal airway on the basis of results from
previous studies (Alexis, Eldridge, Reed, Bromberg, & Peden 2001). As this was a pilot
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study to determine if regional adaptation to LPS can occur, it was decided to design the
study to optimize the likelihood of observing changes in neutrophil numbers.
This model of endotoxin adaptation in the nasal airway can be easily employed to examine
changes at the functional and genetic level in epithelial and monocytic cells recovered from
the nasal airway after challenge. It has also been found that GM-CSF may reverse
attenuation of cellular response to LPS. It has been shown that allergen challenge enhances
expression of CD14 levels in the airway, and we have found that allergen coupled with LPS
response in the nasal airway augments response to LPS. Allergen challenge augments levels
of GM-CSF, and the ability to attenuate the response to LPS may be abrogated in
asthmatics, or following allergen challenge. This model of LPS adaptation in this report
coupled with nasal allergen challenge would allow for examination of the effect of TH2
inflammation's ability to attenuate the response to LPS. LPS is an important component of
airborne particulates and bio-aerosols and is associated with asthma exacerbation. It seems
plausible that allergic inflammation may enhance the susceptibility of asthmatics to PM by
attenuating response to repeated exposure LPS.
Conclusions
In summary, our data show that regional adaptation to repeat LPS can be induced in the
nasal airways of healthy individuals as evidenced by attenuation in PMN response and lower
IL-8 production. This study was not set up to analyze mechanisms for such changes. This
study can form the basis for future studies looking at interaction of repeat LPS exposure
prior to antigen challenge in healthy and atopic subjects.
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Significant increased PMN response after LPS challenge on Day 1.
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Similar PMN response after LPS challenge in Day 1 LPS nare and Day 3 saline nare.
Significantly decreased (after log transformation) PMN response in Day 3 LPS nare
compared with Day 3 saline nare (*p = 0.03) and Day 1 LPS nare (#p = 0.05).
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Lower sCD14 levels after Day 3 LPS challenge in nare that received repeat LPS as opposed
to nare that receive saline on two previous days.
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Significant decrease in IL-8 on Day 3 LPS challenge in nare with repeat LPS challenges as
opposed to the nare that received saline on two prior days.
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Table 1
Subject characteristics and baseline lung function.
Age (yrs) Gender (M/F) Race Height (cm) Weight (kg) FVC % pred. FEV1 % pred.
Mean (N = 15) 29.4 7 M 8 F 7 C 7 AA 1 A 172.0 71.7 100.0 96.0
SEM 2.4 3.8 3.1 4.0 4.0
Range 21–46 152–195 50–93 83–122 82–128
C, Caucasian; AA, African American; A, Asian; SEM, standard error of the mean; FVC, forced vital capacity; FEV1, forced expiratory volume in
1 s; % pred., % predicted.
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Table 2
Absolute total and differential cell counts in nasal lavage mean (±SEM), n = 15 unless specifically noted.
Cell variable PreD1 saline nare PreD1 LPS nare PostD1 saline nare PostD1 LPS nare PostD3 saline nare PostD3 LPS nare











*,# 175 (79) 82 (23)
Mac/mg 26 (9) n = 9 10 (4) n = 8 7 (4) n = 5 11 (5) n = 8 5 (2) n = 7 14 (6) n = 8
TCC/mg, total cell counts per mg sputum; PMN/mg, polymorphonuclear neutrophils per mg sputum; Mac/mg, macrophage per mg sputum.
*
Significantly higher PMN in LPS nare compared with saline nare after Day 1 challenge (p = 0.001).
#
Significantly higher PMN in LPS nare after Day 1 challenge compared with baseline same nare (p = 0.002).
+
Significantly higher TCC in LPS nare compared with saline nare after Day1 challenge (p < 0.05).
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Table 3
Baseline adjusted mean (±SEM) total cell and PMN counts after challenges Days 1 and 3.
Cell variable PostDl–PreD1 saline nare PostD1–PreD1 LPS nare PostD3–PreD1 saline nare PostD3–PreD1 LPS nare









Significantly decreased PMN response (after log transformation) in LPS nare on Day 3 as compared with Day 1 LPS challenge in same nare (p =
0.05).
#
Significantly decreased PMN response (after log transformation) in LPS nare on Day 3 as compared with Day 3 LPS challenge in saline nare (p =
0.03).
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Table 4
Fluid phase components recovered from nasal lavages on Day 3, mean (±SEM). N = 15 unless specifically
noted.











IL-6 194 (96) 112 (38)
IL-1β 98 (46) 53 (19)
GM-CSF 302 (59), n = 9 323 (44), n = 10
ECP 23 (7), n = 7 17 (11), n = 7
*
Significant decrease in IL-8 in nare with repeat LPS challenges as opposed to the nare that received saline on two prior days (p = 0.03).
#
Trending toward significant decrease in sCD14 in nare with repeat LPS challenges as opposed to the nare that received saline on two prior days (p
= 0.06).
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